Search - tctmd.com

Displaying 741 - 760 of 1163

Sort: Relevancy | Date

Presentation TCT 2017

TCT 29: Mechanism of Low Fractional Flow Reserve in Lesions Without Angiographic Significant Stenosis: Role of Hidden Plaque Burden

Presenter: Justin E. Davies, Bernard De Bruyne, Jonghanne Park, MD

October 31, 2017

Presentation TCT 2017

TCT 67: Clinical Relevance of Functionally Insignificant Moderate Coronary Artery Stenosis Assessed by 3-vessel Fractional Flow Reserve Measurement

Presenter: Allen Jeremias, Amir Lerman, Jonghanne Park, MD

October 31, 2017

Presentation TCT 2017

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Presenter: Patrick W. Serruys, David J. Cohen

October 31, 2017

Presentation TCT 2017

Switzerland Presents: A Case of Severe Symptomatic Aortic Stenosis and Complex Coronary Artery Disease - ECMO Support?

Presenter: Hyo-Soo Kim, Quang Ngoc Nguyen, Stephane Noble

October 31, 2017

Presentation TCT 2017

Optimal Technique 1: Hemodynamic Assessment of Renal Stenosis

Presenter: Michael R. Jaff, Stephen C. Textor, Massoud A. Leesar

October 31, 2017

Presentation TCT 2017

Case #2 Introduction: 85-Year-Old Patient With Previous Stents and Severe Aortic Stenosis, Reduced LVEF, Chronic Anemia, and Mild Renal Impairment Develops Atrial Fibrillation After TAVR

Presenter: Nick Curzen, Rod H. Stables

October 31, 2017

Presentation TCT 2017

Case #1 Introduction: Low-Risk 65-Year-Old Patient With Severe Aortic Stenosis Refuses Surgical TAVR Because They Want TAVR

Presenter: Nick Curzen, Rod H. Stables

October 31, 2017

Presentation TCT 2017

When is TAVR Indicated for Low Gradient AS With Preserved Ejection Fraction? Case Examples

Presenter: Mackram F. Eleid

October 30, 2017

Presentation TCT 2017

Clinical Management of Low Flow-Low Gradient AS: The Role of TAVR

Presenter: Howard C. Herrmann

October 30, 2017

Presentation TCT 2017

Classifying Aortic Stenosis According to Pathophysiology and Hemodynamics An Echocardiographers Perspective

Presenter: Philippe Pibarot

October 30, 2017

Presentation TCT 2017

How to Optimally Perform Valve-in-Valve Implantation in a Small Surgical Valve (Including Bioprosthetic Valve Fracture) Case Examples

Presenter: Danny Dvir

October 30, 2017

Presentation TCT 2017

Important Clinical Lessons From the VIVID Registry and the PARTNER Experience

Presenter: John G. Webb

October 30, 2017

Presentation TCT 2017

Understanding Surgical Aortic Valve Anatomy: Implications for Valve-in-Valve Therapy

Presenter: Vinayak Bapat

October 30, 2017

Presentation TCT 2017

The NOTION 2 Low-risk Trial in Younger Patients

Presenter: Lars Sondergaard

October 30, 2017

Presentation TCT 2017

The Evolut R Low-risk Trial

Presenter: Jeffrey J. Popma

October 30, 2017

Presentation TCT 2017

The PARTNER 3 Low-risk Trial

Presenter: Michael J. Mack

October 30, 2017

Presentation TCT 2017

The UK All-comer TAVI Study

Presenter: Neil E. Moat

October 30, 2017

Presentation TCT 2017

Viewpoint #2: Not So Fast! GARY and Other Studies Indicate an Important Role for Surgery in Intermediate-risk Patients

Presenter: Thomas Walther

October 30, 2017

Presentation TCT 2017

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Presenter: Michael J. Reardon

October 30, 2017

Presentation TCT 2017

Insights From the New 2017 ESC Valve Disease Guidelines: Changes in the Management of Aortic Stenosis

Presenter: Martin B. Leon, Patrick T. O'Gara, Olaf Wendler

October 30, 2017

Advertisement

TCT 29: Mechanism of Low Fractional Flow Reserve in Lesions Without Angiographic Significant Stenosis: Role of Hidden Plaque Burden

TCT 67: Clinical Relevance of Functionally Insignificant Moderate Coronary Artery Stenosis Assessed by 3-vessel Fractional Flow Reserve Measurement

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Switzerland Presents: A Case of Severe Symptomatic Aortic Stenosis and Complex Coronary Artery Disease - ECMO Support?

Optimal Technique 1: Hemodynamic Assessment of Renal Stenosis

Case #2 Introduction: 85-Year-Old Patient With Previous Stents and Severe Aortic Stenosis, Reduced LVEF, Chronic Anemia, and Mild Renal Impairment Develops Atrial Fibrillation After TAVR

Case #1 Introduction: Low-Risk 65-Year-Old Patient With Severe Aortic Stenosis Refuses Surgical TAVR Because They Want TAVR

When is TAVR Indicated for Low Gradient AS With Preserved Ejection Fraction? Case Examples

Clinical Management of Low Flow-Low Gradient AS: The Role of TAVR

Classifying Aortic Stenosis According to Pathophysiology and Hemodynamics An Echocardiographers Perspective

How to Optimally Perform Valve-in-Valve Implantation in a Small Surgical Valve (Including Bioprosthetic Valve Fracture) Case Examples

Important Clinical Lessons From the VIVID Registry and the PARTNER Experience

Understanding Surgical Aortic Valve Anatomy: Implications for Valve-in-Valve Therapy

The NOTION 2 Low-risk Trial in Younger Patients

The Evolut R Low-risk Trial

The PARTNER 3 Low-risk Trial

The UK All-comer TAVI Study

Viewpoint #2: Not So Fast! GARY and Other Studies Indicate an Important Role for Surgery in Intermediate-risk Patients

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Insights From the New 2017 ESC Valve Disease Guidelines: Changes in the Management of Aortic Stenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content